MAMMANO Fabrizio : UMR_S941 : Viral Evolution and Pathogenesis

Unit : INSERM UMR_S941 Génétique des Virus et Pathogénèse des Maladies Virales - Université Paris Diderot

INSERM UMR_S94I  Génétique des Virus et Pathogénèse des Maladies Virales
IUH Bâtiment Hayem
Hôpital Saint-Louis
1, avenue Claude Vellefaux
75010 PARIS

Speciality : Department IM

Director of the unit : François CLAVEL

Principal investigator :

MAMMANO Fabrizio
Email : fabrizio.mammanoSPAMFILTER@inserm.fr Phone number: +33 (0)1 57 27 67 57

Composition of research team :

  • MAMMANO Fabrizio (DR2-INSERM, HDR)
  • SARAGOSTI Sentob (DR2-INSERM, HDR)
  • MOLINA Jean-Michel (PU-PH, HDR)
  • DELAUGERRE Constance (MCU-PH, HDR)
  • MAZERON Marie-Christine (MCU-PH, HDR)
  • SCHNEPF Nathalie (PHC)

5 Recent publications of the research team :

Monel B., Beaumont E., Vendrame D., Schwartz O., Brand D., and Mammano F. HIV cell-to-cell transmission requires the production of infectious virus particles, and does not proceed through Env-mediated fusion pores. Journal of Virology, 2012 (PMID: 22258237)

Nguyen T.T.N., Rato S. Molina J.M., Clavel F., Delaugerre C., Mammano F. Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations.  Journal of Antimicrobial Chemotherapy, 2014. (PMID: 25336162)

Ikeda H., Godinho-Santos A., Rato S., Vanwalscappel B., Clavel F., Aihara K., Iwami S., and Mammano F. Quantifying the Antiviral Effect of IFN on HIV-1 Replication in Cell Culture.  Scientific Reports, 2015 (PMID: 26119462)

Gallien S, Flandre P, Nguyen N, De Castro N, Molina JM, Delaugerre C. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1. Journal of Medical Virology. 2015 (PMID : 25070158).

Remion A., Delord M., Hance A.J., Saragosti S., and Mammano F. Kinetics of the establishment of HIV-1 viral interference and comprehensive analysis of the contribution of viral genes.  Virology, 2016 (PMID: 26499042).